Clearmind Medicine (NASDAQ:CMND) Issues Quarterly Earnings Results

Clearmind Medicine (NASDAQ:CMND) posted its quarterly earnings results on Thursday. The company reported ($0.57) earnings per share (EPS) for the quarter, FiscalAI reports.

Clearmind Medicine Price Performance

Clearmind Medicine stock traded down $0.08 during midday trading on Thursday, reaching $0.98. The stock had a trading volume of 97,591 shares, compared to its average volume of 1,027,166. Clearmind Medicine has a twelve month low of $0.92 and a twelve month high of $524.00. The firm has a market cap of $1.00 million, a price-to-earnings ratio of -0.01 and a beta of 0.81. The firm’s fifty day simple moving average is $1.76 and its two-hundred day simple moving average is $5.01.

Insider Activity

In other news, major shareholder Financial Lp Hrt sold 22,139 shares of the stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $3.31, for a total value of $73,280.09. Following the completion of the sale, the insider owned 81,353 shares in the company, valued at $269,278.43. This represents a 21.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 27,424 shares of company stock valued at $90,910 in the last ninety days.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised Clearmind Medicine from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 20th.

Clearmind Medicine Company Profile

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.